Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Safety of late in utero exposure to zidovudine in infants born to human immunodeficiency virus-infected mothers: Bangkok
Autore:
Chotpitayasunondh, T; Vanprapar, N; Simonds, RJ; Chokephaibulkit, K; Waranawat, N; Mock, P; Chuachoowong, R; Young, N; Mastro, TD; Shaffer, N;
Indirizzi:
HIV AIDS Collaborat, Nonthaburi, Thailand HIV AIDS Collaborat NonthaburiThailand ollaborat, Nonthaburi, Thailand Mahidol Univ, Fac Med Siriraj Hosp, Bangkok 10700, Thailand Mahidol Univ Bangkok Thailand 10700 iriraj Hosp, Bangkok 10700, Thailand Minist Publ Hlth, Dept Med Serv, Queen Sirikit Natl Inst Child Hlth, Bangkok, Thailand Minist Publ Hlth Bangkok Thailand tl Inst Child Hlth, Bangkok, Thailand Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA Ctr Dis Control & Prevent Atlanta GA USA V AIDS Prevent, Atlanta, GA USA
Titolo Testata:
PEDIATRICS
fascicolo: 1, volume: 107, anno: 2001,
pagine: NIL_36 - NIL_41
SICI:
0031-4005(200101)107:1<NIL_36:SOLIUE>2.0.ZU;2-Z
Fonte:
ISI
Lingua:
ENG
Soggetto:
NUCLEOSIDE ANALOGS; IN-UTERO; TRANSMISSION; THAILAND; TYPE-1; SUBSET; WOMEN; TRIAL;
Keywords:
zidovudine; vertical HIV transmission; children; disease progression; Thailand;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
24
Recensione:
Indirizzi per estratti:
Indirizzo: Simonds, RJ Minist Publ Hlth, DMS 6 Bldg,Tivanon Rd, Nonthaburi 11000, Thailand Minist Publ Hlth DMS 6 Bldg,Tivanon Rd Nonthaburi Thailand 11000
Citazione:
T. Chotpitayasunondh et al., "Safety of late in utero exposure to zidovudine in infants born to human immunodeficiency virus-infected mothers: Bangkok", PEDIATRICS, 107(1), 2001, pp. NIL_36-NIL_41

Abstract

Background. Short-course zidovudine (ZDV) given in the late antenatal period can reduce mother-infant human immunodeficiency virus (HIV) transmissionby one half. Because this intervention is being implemented in developing countries, evidence of its safety is needed. Methods. In a randomized, double-blinded, placebo-controlled trial in Bangkok, HIV-infected pregnant women received either ZDV (300 mg twice daily from 36 weeks' gestation until labor, then every 3 hours until delivery) or an identical placebo regimen. Infants were evaluated at birth and at 1, 2, 4, 6, 9, 12, 15, and 18 months of age. Growth, clinical events, and hematologic and immunologic measurements were compared between treatment groups. Results. Of the 395 children born (196 in ZDV group and 199 in placebo group), 330 were uninfected, 55 were infected, and 10 had indeterminate infection status. Overall, 319 children (81%) completed 18 months of follow-up, and 14 (4%) died before 18 months of age. Among uninfected children, the mean hematocrit was lower in the ZDV group at birth (49.1% vs 51.5%) but not at later ages; mean weight, height, head circumference, and CD4(+) and CD8(+) T lymphocyte counts were similar in both groups at all ages. Five uninfected children in the ZDV group but only one in the placebo group had a febrile convulsion. No other signs suggestive of mitochondrial dysfunction and no tumors were observed. Among infected children, an estimated 62% in the ZDV group and 77% in the placebo group survived free of Centers for Disease Control and Prevention class C disease during the 18-month follow-up. Conclusions. No significant adverse events were associated with short-course ZDV during 18 months of follow-up in this population.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/03/20 alle ore 15:09:44